Dermbits - Watch short videos of KOLs answering your questions

Conditions & Treatments
Learn from the Experts
Support Your Practice
Conferences & Highlights
Community Resources
Our Expert Network

CME & Education About Us

Loading...

CME & Education About Us

Loading profile...

Conditions & Treatments
Learn from the Experts
Support Your Practice
Conferences & Highlights
Community Resources
Our Expert Network

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved

Dermbits - Watch short videos of KOLs answering your questions

Dermbits

hero

Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

Psoriasis

What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence?

Featuring James Del Rosso, DO

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

Psoriasis

What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”?

Featuring James Del Rosso, DO

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

Psoriasis

Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease?

Featuring James Del Rosso, DO

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

Psoriasis

What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments?

Featuring James Del Rosso, DO

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

Psoriasis

What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast?

Featuring James Del Rosso, DO

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

Psoriasis

Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios?

Featuring James Del Rosso, DO

When apremilast first launched, how was it positioned, and what do we understand differently now?

Psoriasis

When apremilast first launched, how was it positioned, and what do we understand differently now?

Featuring James Del Rosso, DO

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?

Atopic Dermatitis

How do you frame quality-of-life impact when requesting coverage for ruxolitinib?

Featuring Tina Bhutani-Jacques, MD, MAS

When do bridge programs make the most clinical sense for patients?

Atopic Dermatitis

When do bridge programs make the most clinical sense for patients?

Featuring Tina Bhutani-Jacques, MD, MAS

How do you document treatment goals when requesting newer therapies?

Atopic Dermatitis

How do you document treatment goals when requesting newer therapies?

Featuring Tina Bhutani-Jacques, MD, MAS

How do you document medical necessity when disease severity seems borderline?

Atopic Dermatitis

How do you document medical necessity when disease severity seems borderline?

Featuring Tina Bhutani-Jacques, MD, MAS

What clinical language resonates most with payers during prior authorization review?

Atopic Dermatitis

What clinical language resonates most with payers during prior authorization review?

Featuring Tina Bhutani-Jacques, MD, MAS

How do you document body surface area or lesion burden for ruxolitinib coverage decisions?

Atopic Dermatitis

How do you document body surface area or lesion burden for ruxolitinib coverage decisions?

Featuring Tina Bhutani-Jacques, MD, MAS

When might ruxolitinib cream be appropriate earlier in the treatment pathway?

Atopic Dermatitis

When might ruxolitinib cream be appropriate earlier in the treatment pathway?

Featuring Tina Bhutani-Jacques, MD, MAS

What is the single most meaningful management decision that becomes clearer after genomic testing?

Precision Medicine

What is the single most meaningful management decision that becomes clearer after genomic testing?

Featuring David Cotter, MD, PhD

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

Precision Medicine

Where do you think clinicians are most likely to misinterpret or overextend genomic test results?

Featuring David Cotter, MD, PhD

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

Precision Medicine

What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx?

Featuring David Cotter, MD, PhD

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

Precision Medicine

Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively?

Featuring David Cotter, MD, PhD

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

Precision Medicine

What can AdvanceAD-TX tell you that clinical phenotype alone does not?

Featuring David Cotter, MD, PhD

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

Precision Medicine

How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases?

Featuring David Cotter, MD, PhD

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Precision Medicine

Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice?

Featuring David Cotter, MD, PhD

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

Precision Medicine

Has the DecisionDx Melanoma test influenced your imaging threshold in select patients?

Featuring David Cotter, MD, PhD

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

Precision Medicine

How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align?

Featuring David Cotter, MD, PhD

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

Precision Medicine

How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology?

Featuring David Cotter, MD, PhD

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?

Precision Medicine

Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management?

Featuring David Cotter, MD, PhD

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?

Precision Medicine

Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions?

Featuring David Cotter, MD, PhD

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?

Precision Medicine

In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary?

Featuring David Cotter, MD, PhD

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

Psoriasis

What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?

Featuring Neal Bhatia, MD

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

Psoriasis

How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?

Featuring Neal Bhatia, MD

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

Psoriasis

When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?

Featuring Neal Bhatia, MD

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

Psoriasis

In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?

Featuring Neal Bhatia, MD

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

Psoriasis

How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?

Featuring Neal Bhatia, MD

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

Psoriasis

In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?

Featuring Neal Bhatia, MD

What clinical details make an appeal letter more persuasive?

Atopic Dermatitis

What clinical details make an appeal letter more persuasive?

Featuring Dawn Merritt, DO

What supporting materials help overturn a denial?

Atopic Dermatitis

What supporting materials help overturn a denial?

Featuring Dawn Merritt, DO

When do you escalate from prior auth to formal appeal?

Atopic Dermatitis

When do you escalate from prior auth to formal appeal?

Featuring Dawn Merritt, DO

What’s one documentation habit that consistently improves approvals?

Atopic Dermatitis

What’s one documentation habit that consistently improves approvals?

Featuring Dawn Merritt, DO

How do you document steroid failure before prescribing ruxolitinib cream?

Atopic Dermatitis

How do you document steroid failure before prescribing ruxolitinib cream?

Featuring Dawn Merritt, DO

What helps secure coverage for ruxolitinib in step therapy plans?

Atopic Dermatitis

What helps secure coverage for ruxolitinib in step therapy plans?

Featuring Dawn Merritt, DO

What documentation details helps support approval for ruxolitinib cream?

Topical Therapies

What documentation details helps support approval for ruxolitinib cream?

Featuring Alexandra Golant, MD

Can EHR templates improve access for new therapies like ruxolitinib?

Topical Therapies

Can EHR templates improve access for new therapies like ruxolitinib?

Featuring Alexandra Golant, MD

What are common documentation mistakes that delay access to newer topicals?

Topical Therapies

What are common documentation mistakes that delay access to newer topicals?

Featuring Alexandra Golant, MD

What’s key to documenting steroid failure or intolerance clearly?

Topical Therapies

What’s key to documenting steroid failure or intolerance clearly?

Featuring Alexandra Golant, MD

How do you talk to patients when access issues delay treatment?

Topical Therapies

How do you talk to patients when access issues delay treatment?

Featuring Alexandra Golant, MD

What’s your top access tip for new clinicians balancing care and paperwork?

Topical Therapies

What’s your top access tip for new clinicians balancing care and paperwork?

Featuring Alexandra Golant, MD

How does the MyPath Melanoma test differ from standard histopathologic evaluation?

Cutaneous Melanoma

How does the MyPath Melanoma test differ from standard histopathologic evaluation?

Featuring Brent Moody, MD

When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?

Cutaneous Melanoma

When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion?

Featuring Brent Moody, MD

How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant?

Cutaneous Melanoma

How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant?

Featuring Brent Moody, MD

48 of 939

Previous page Next page